Oncologists were willing to prescribe treatments that cost $245,972 per quality-adjusted life-year (QALY; SD $243,663 per QALY) in life-prolonging situations v. only $119,082 per QALY (SD $197,048 per QALY) for treatmentsthat improve quality of life but do not prolong survival. This difference did not depend on age, gender, percentage of time in clinical work, or self-reported preparedness to use and interpret cost-effectiveness information.
It would interesting to see if new life extension treatments became available whether any kind of similar spending prescriptions would carry over. It would probably be difficult to sustain more than 20% of a persons income and 20% of tax revenue for effective life extension treatment.
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks